Abstract
The finding that cyclooxygenase-2 (COX-2) is over-expressed and plays an important role in carcinogenesis in gastrointestinal (GI) cancers including esophagus, gastric and colorectal cancers has triggered the researches of COX-2 inhibitors as the chemopreventive option for GI cancers. This reviewer updates the current molecular biology on the regulation of COX-2 expression, pharmacological concepts of COX-2 inhibitors in the chemoprevention of GI tract, the clinical efficacies of COX -2 inhibitors in prevention of cancers in GI tract and associated main adverse events. In inflammation, COX-2 expression is regulated both at the transcriptional and posttranscriptional levels. Hypermethylation of the CpG island in the COX-2 gene is the major cause of COX-2 silencing in a subset of GI cancers. However, the tumor-inhibitory efficacy of non-selective non-steroidal antiinflammatory drugs (NSAIDs) or selective COX-2 inhibitors is not necessarily related to their COX-inhibitory potential. These compounds harbor additional pharmacological activities that are entirely independent of its COX-2 inhibitory activity. The clearly identified targets relevant for anticancer therapy, the benefits from clinical chemoprevention of GI tract cancers and the absence of adverse findings of cardiovascular function or histopathology in preclinical toxicology studies indicate the promising results of COX-2 inhibitors. The efficacy and toxicity of NSAIDs are a consequence of the inhibition of the COX enzymes. Therefore, an optimal regime of COX-2 inhibitors in chemoprevention of GI cancers should be further investigated probably by adjustment of dosage, duration, integration of co-therapy and careful selection of candidates.
Keywords: Cyclooxygenase 2, esophagus cancer, gastric cancer, colorectal cancer, Cyclooxygenase 2 inhibitor, aspirin, celecoxib, rofecoxib, carcinogenesis, dosage
Current Pharmaceutical Design
Title:Chemoprevention of Cancers in Gastrointestinal Tract with Cyclooxygenase 2 Inhibitors
Volume: 19 Issue: 1
Author(s): Rui Wang, Linjie Guo, Pu Wang, Wenjuan Yang, Yaoyao Lu, Zhiyin Huang and Chengwei Tang
Affiliation:
Keywords: Cyclooxygenase 2, esophagus cancer, gastric cancer, colorectal cancer, Cyclooxygenase 2 inhibitor, aspirin, celecoxib, rofecoxib, carcinogenesis, dosage
Abstract: The finding that cyclooxygenase-2 (COX-2) is over-expressed and plays an important role in carcinogenesis in gastrointestinal (GI) cancers including esophagus, gastric and colorectal cancers has triggered the researches of COX-2 inhibitors as the chemopreventive option for GI cancers. This reviewer updates the current molecular biology on the regulation of COX-2 expression, pharmacological concepts of COX-2 inhibitors in the chemoprevention of GI tract, the clinical efficacies of COX -2 inhibitors in prevention of cancers in GI tract and associated main adverse events. In inflammation, COX-2 expression is regulated both at the transcriptional and posttranscriptional levels. Hypermethylation of the CpG island in the COX-2 gene is the major cause of COX-2 silencing in a subset of GI cancers. However, the tumor-inhibitory efficacy of non-selective non-steroidal antiinflammatory drugs (NSAIDs) or selective COX-2 inhibitors is not necessarily related to their COX-inhibitory potential. These compounds harbor additional pharmacological activities that are entirely independent of its COX-2 inhibitory activity. The clearly identified targets relevant for anticancer therapy, the benefits from clinical chemoprevention of GI tract cancers and the absence of adverse findings of cardiovascular function or histopathology in preclinical toxicology studies indicate the promising results of COX-2 inhibitors. The efficacy and toxicity of NSAIDs are a consequence of the inhibition of the COX enzymes. Therefore, an optimal regime of COX-2 inhibitors in chemoprevention of GI cancers should be further investigated probably by adjustment of dosage, duration, integration of co-therapy and careful selection of candidates.
Export Options
About this article
Cite this article as:
Wang Rui, Guo Linjie, Wang Pu, Yang Wenjuan, Lu Yaoyao, Huang Zhiyin and Tang Chengwei, Chemoprevention of Cancers in Gastrointestinal Tract with Cyclooxygenase 2 Inhibitors, Current Pharmaceutical Design 2013; 19 (1) . https://dx.doi.org/10.2174/1381612811306010115
DOI https://dx.doi.org/10.2174/1381612811306010115 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pro-Inflammatory Cytokines and their Actions on the Metabolic Disturbances Associated with Cancer: Implications in Cachexia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Cucurbitacin B Enhances the Anticancer Effect of Imatinib Mesylate Through Inhibition of MMP-2 Expression in MCF-7 and SW480 Tumor Cell Lines
Anti-Cancer Agents in Medicinal Chemistry The Role of JNK Signalling in Responses to Oxidative DNA Damage
Current Drug Targets Heparin Affin Regulatory Peptide: A New Target for Tumour Therapy?
Current Cancer Drug Targets Patent Selections:
Recent Patents on Food, Nutrition & Agriculture Fused Aryl-Phenazines: Scaffold for the Development of Bioactive Molecules
Current Drug Targets A Novel Approach to Anticancer Therapies: Peroxisome Proliferator Activator-Receptor-γ as a New Target Therapy in the Treatment of Human Urological Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets The Significance of Ubiquitin Proteasome Pathway in Cancer Development
Recent Patents on Anti-Cancer Drug Discovery Reactive Oxygen Species in the Initiation of IL-4 Driven Autoimmunity as a Potential Therapeutic Target
Current Pharmaceutical Design Innovations and Opportunities to Improve Conventional (Deoxy)Nucleoside and Fluoropyrimidine Analogs in Cancer
Current Medicinal Chemistry Lumiflavin Enhances the Effects of Ionising Radiation on Ovarian Cancer Stem-Like Cells by Inhibiting Autophagy
Anti-Cancer Agents in Medicinal Chemistry A Historical Overview of the Heterologous Expression of Mammalian UDP-Glucuronosyltransferase Isoforms Over the Past Twenty Years
Current Drug Metabolism Small Molecule Drugs and Targeted Therapy for Melanoma: Current Strategies and Future Directions
Current Medicinal Chemistry Bcl-2 Inhibitors: Emerging Drugs in Cancer Therapy
Current Medicinal Chemistry Editorial [Hot Topic: Drugs and Pregnancy (Guest Editor: Zaneta Kimber-Trojnar)]
Current Pharmaceutical Biotechnology Cellular Senescence in the Development and Treatment of Cancer
Current Pharmaceutical Design The Targets of Curcumin
Current Drug Targets Targeting Chemokine Receptor CXCR4 for Treatment of HIV-1 Infection, Tumor Progression, and Metastasis
Current Topics in Medicinal Chemistry The Use of Fas Ligand, TRAIL and Bax in Gene Therapy of Prostate Cancer
Current Gene Therapy TGF-β2 Signaling in High-Grade Gliomas
Current Pharmaceutical Biotechnology